Syngene Q1 FY 2024 revenue up 26% to Rs. 832 crores, PAT up 26% to Rs.93 Cr
Acquisition of biologics manufacturing facility in Bangalore to complete by the end of the third quarter in FY 24
Acquisition of biologics manufacturing facility in Bangalore to complete by the end of the third quarter in FY 24
Evonik specializes in mid- to large-scale, later clinical phase HPAPIs
Adding 20,000 liters of installed biologics drug substance manufacturing capacity
As Caeregen’s CDMO partner for CTR-107, Wacker Biotech will produce drug substance at its site in Halle, Germany, and complete clinical trial drug product production at its site in Amsterdam, the Netherlands
Sajjan India Limited is looking for expansion, both organically and through acquisitions, to achieve the planned growth
Records revenue growth of 22% to Rs. 762 crores in Q4 FY23 and grew 30% to Rs. 3149 crores in FY23
The R&D Center significantly increases Siegfried’s R&D capacity to drive further growth
Aji Bio-Pharma has six fill finish lines located in San Diego, including a new line
To enable company to be future-ready by tapping potential in CDMO space
Subscribe To Our Newsletter & Stay Updated